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A B S T R A C T
Purpose: Human papillomavirus (HPV) vaccination in the United States remains a public
health challenge with vaccine rates of 50%. Although health care providers can facilitate HPV
vaccination, several factors may impede their ability to universally recommend the vaccine. To
maximize the potential of HPV vaccines, it is important to understand challenges providers
face in the clinical environment. The study sought to identify factors associated with
recommendation of the HPV vaccine for low-income adolescents in the early (9e10), target
(11e12), early adolescent catch-up (13e14), and late adolescent catch-up (15e17) vaccination
groups.
Methods: Surveys were mailed between October 2009 and April 2010 to a random sample of
Florida-based physicians serving Medicaid-enrolled adolescents. Data were analyzed in 2013.
Results: Among early adolescents, discomfort discussing sexually transmitted infections (STIs)
with teens (odds ratio [OR] ¼ 1.75), difficulty ensuring vaccine completion (OR ¼ .73), and
discomfort discussing STIs with parents (OR ¼ .44) were associated with recommendation. For
target adolescents, discomfort discussing STIs with teens (OR ¼ 2.45), time constraints (OR ¼ .70),
vaccine efficacy concerns (OR ¼ .65), discomfort discussing STIs with parents (OR ¼ .33),
obstetrics/gynecology (OR ¼ .25) and family medicine (OR ¼ .24) specialty, and non-Hispanic
black patient (OR ¼ .15) were associated with recommendation. In early catch-up adolescents,
concerns that teens will practice riskier behaviors (OR ¼ .57), discomfort discussing STIs with
parents (OR ¼ .47), and family medicine specialty (OR ¼ .20) were associated with recommen-
dation. For late catch-up adolescents, family medicine specialty (OR ¼ .13) was associated with
recommendation.
Conclusions: Modifiable factors that impede or influence provider recommendations of HPV
vaccines can be addressed through intervention. Overall, findings suggest that efforts should focus
on sexuality communication and family medicine specialty.
 2014 Society for Adolescent Health and Medicine. All rights reserved.
IMPLICATIONS AND
CONTRIBUTION
Identifying barriers to HPV
vaccine recommendation
among providers who
largely see low-incomeand
minority patients is essen-
tial to reducing down-
stream HPV-associated
health disparities. Specifi-
cally, efforts to improve
recommendation practices
should focus on building
providers’ communication
skills around sexual health
and more readily engaging
family medicine physicians
in the vaccination dialogue.
Human papillomavirus (HPV) vaccination rates have gradu-
ally increased in the United States. The nationwide vaccine
initiation rate (i.e., at least one of three dose series administered)
increased by 29% from 2007 (25%) to 2011 (53%) among
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adolescent girls aged 13e17 [1,2]. Despite this increase, the
promise of HPV vaccines to effect downstream trends in racial,
economic, and geographic health disparities is realized only
when vaccination is maximized across populations [3]. Low-
income and racial/ethnic minority adolescent girls face addi-
tional vaccination challenges such as lower rates of provider
recommendation for vaccination and vaccine series completion
[2,4,5]. Such findings highlight the urgent need to understand
these differences in light of the disproportionate burden of
cervical cancer and other HPV-associated diseases among low-
income and minority groups [6].
Approximately 74% of all HPV infections occur among young
adults aged 15e24 [7]. As such, the Centers for Disease Control
and Prevention recommends target vaccination for adolescent
girls and boys aged 11e12, early vaccination for those aged 9e10,
and catch-up vaccination for 13e26 year olds [8,9]. HPV vaccines
have the potential to reduce HPV-related morbidity and
mortality through widespread and non-disparate uptake [10,11].
Research suggests that health care provider recommendation is
an important contributor to HPV vaccine initiation and comple-
tion [4,12e14]. Prior studies have found that adolescent girls who
received an HPV vaccine recommendation from their health care
provider were 5 to 23 times more likely to vaccinate compared
with those without a recommendation [4,13,15].
Few studies have examined health care provider barriers to
recommending the HPV vaccine. Daley et al. found that the need
to discuss sexuality before recommendation and prior vaccine
refusals were barriers to recommendation among adolescents in
the target vaccination age range [16]. Another study found that
inadequate reimbursement was solely related to not recom-
mending vaccination for adolescent girls of all ages [17]. Other
studies found that negative parental perceptions of the vaccine,
HPV knowledge deficits, lack of support for mandatory vaccina-
tion, lack of office coordination, and difficulty determining
insurance coverage were barriers to recommendation [18e20].
Although some studies have outlined provider barriers to HPV
vaccine recommendation, these studies did not account for
differences by age- and evidence-based recommendation
guidelines and have not primarily focused on providers who see
low-income patients [16,17]. Such an examination is important
given that physicians’ vaccination barriers may differ according
to age. Likewise, focusing on recommendation patterns among
physicians who see low-income and minority patients is
important given that these groups carry a disproportionate
burden of HPV-associated disease. Thus, the purpose of this
study was to assess factors related to Medicaid providers’
recommendation of the HPV vaccine across all three vaccination
categories: early, target, and catch-up.
Methods
Study design
This study is part of a larger study that assessed HPV infor-
mation seeking behaviors, knowledge, perceptions, vaccination
barriers and practices, and sociodemographic and clinic charac-
teristics of Florida Medicaid providers [21]. Using the Dillman
[22] multiphase recruitment approach, surveys were mailed to
a random sample of Medicaid providers selected from the Florida
MedicaidMaster Provider File who had a clinical practice address
in Florida. The multiphase recruitment approach consisted of
mailing a: (1) postcard to introduce the study; (2) packet
containing a cover letter, scannable survey, prepaid return
envelope, and $15 cash incentive; (3) reminder card, followed by
another copy of the survey to prompt completion by non-
responders; and (4) third survey packet along with a $15 cash
incentive to those who received the second survey mailing.
Physicians who retuned the survey during the first mailing
received a $15 cash incentive. If the survey was mailed to
physicians a second time, an additional $15 cash incentive was
received to equal a maximum of $30. Data were collected
between October 2009 and April 2010. The study was approved
by the University of South Florida and University of Florida
Institutional Review Boards.
Study setting and population
A random sample of 800 physicians generated from the
FloridaMedicaidMaster Provider Filewas recruited for the study.
Physicians eligible for study inclusion included thosewho saw 25
or more 9- to 17-year-old girls in the past year and had a primary
care specialty. Of the 800 mailed surveys, 485 were completed
and returned. Of those, 52 did not meet eligibility criteria. The
final study sample included 433 physicians. The overall response
rate of 68.3% was calculated by dividing the number of respon-
dents by the number of surveys mailed, minus the undeliverable
and ineligible surveys (485/[800e90]).
Methods of measurement
A multi-item survey, adapted from a previous national study
of HPV vaccination among physicians [23], was used to assess
barriers related to HPV vaccine recommendation. Previous
research reporting on physicians’ barriers to HPV vaccination and
recommendations from study co-investigators, who are both
clinicians and experts in the field, informed the selection of
barrier items for the current survey [16,24,25]. At the time of the
study, Gardasil was the only licensed HPV vaccine in the United
States; therefore, items referred only to Gardasil.
HPV vaccine recommendation. Physicians were asked “In the past
12 months, how often did you recommend the HPV vaccine to
your female Medicaid patients, in the following age groups”.
Physicians responded to the items on a 5-point Likert scale (1 ¼
never; 5 ¼ always). Because we were interested in modeling
barriers associated with recommendation, the five response
categories were collapsed into two, “sometimes/often/always”
(i.e., recommendation) and “never/rarely” (i.e., non-
recommendation). Physicians were asked to respond to the item
for four separate age groups: 9e10 (early vaccination), 11e12
(target vaccination), 13e14 (early catch-up vaccination), and
15e17 (late catch-up vaccination). The age groups were catego-
rized based on the Centers for Disease Control and Prevention
HPV vaccine recommendation guidelines with further stratifica-
tion in the catch-up group [8]. The catch-up group was split into
two based on earlier work within the Florida Medicaid popula-
tion suggesting different vaccination patterns within the two
groups [26].
Barriers to HPV vaccine recommendation. Physicians were asked
a series of 13 items related to their perceptions of vaccination
barriers. Specifically, physicians were asked, “How strongly
would you agree or disagree that the following are barriers
related to immunizing your Medicaid patients against HPV?” The
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barrier items related to vaccine safety and efficacy, sexual
behavior practices of adolescents, information deficits, reim-
bursement and cost, time constraints, discussion of sexually
transmitted infections (STIs), vaccine completion, and school
mandates. Physicians were asked to respond to the items on a 5-
point Likert response scale (1 ¼ strongly disagree; 5 ¼ strongly
agree).
Clinical practice characteristics. Physicians were asked to indicate
their primary clinical specialty (pediatrics, family medicine,
obstetrics/gynecology), racial composition of their patients (non-
Hispanic white, non-Hispanic black, Hispanic, other), number of
Medicaid patients seen on a typical day (<15, 15e19, 20e29,
30), whether they have a vaccine coordinator on staff (yes/no),
and if they are a Vaccines for Children provider (yes/no).
Sociodemographic characteristics. Physicians’ age, race, gender,
and ethnicity were obtained.
Statistical analysis
Frequency distributions and means of sociodemographic and
clinical practice variables were computed. Multivariable logistic
regression was used to model the probability of recommending
the HPV vaccine to adolescent girls aged 9e17. First, multivari-
able logistic regressions were conducted to determine socio-
demographic and clinical practice predictors of recommending
the HPV vaccine. The final multivariate regression models
included significant (p < .05) demographic and practices char-
acteristics identified in the first logistic regression models and
the 13 HPV vaccination barrier variables. Multivariable logistic
regressionmodels were stratified by vaccination age group: early
(9e10), target (11e12), and catch-up (13e14 and 15e17). Nagel-
kerke R2 values provided an indication of the amount of variation
in recommending the HPV vaccine explained by each regression
model. All analyses were conducted in 2013 using SPSS 20.0.
Statistical tests were two-tailed, with alpha level of .05 and 95%
confidence interval (CI) for odds ratios (OR).
Results
Sample characteristics
The largest proportion of physicians was white/Caucasian race
(48%) and non-Hispanic ethnicity (65%). Physicians’ age ranged
from 29 to 79 (mean age 49.76  9.89). There were slightly more
males (54%) than females (45%) and 74% were pediatricians.
Seventy-nine percent were Vaccines for Children providers and
83%had avaccine coordinator on staff.When asked about the race/
ethnicity of their patient population, about 20% reported that the
majority of their Medicaid patients were non-Hispanic white, 22%
non-Hispanic black, 28% Hispanic, and 28% comprised other racial
groups. The largest proportion of Medicaid patients seen in
a typical day was 15e19 (31%) (data not shown).
Early vaccination, 9e10
In total, 34% of physicians reported that they recommend
vaccination for girls in the early (9e10 years) vaccination age
group. In the first logistic regression model including socio-
demographic and clinical practice characteristics, physicians’
race and clinical specialty were associated with HPV vaccine
recommendation and were included in the final model (Table 1).
Discomfort discussing STIs with teens (OR ¼ 1.75; 95% CI,
1.03e2.97) was positively associated, whereas difficulty ensuring
vaccine completion (OR ¼ .73; 95% CI, .58e.92) and discomfort
discussing STIs with parents (OR ¼ .44; 95% CI, .25e.76) were
negatively associated with HPV vaccine recommendation in the
final logistic regression model (Table 2). The final model
explained 13% of the variance of physicians’ HPV vaccine
recommendation.
Target vaccination, 11e12
Approximately 74% of physicians reported that they recom-
mend vaccination for 11- to 12-year-old adolescent girls. In the
model including only sociodemographic and clinical practice
variables, physician ethnicity, clinical specialty, and patients’ race
were significantly associated with HPV vaccine recommendation
and thus were included in the final model (Table 1). In the final
model, discomfort discussing STIs with teens (OR ¼ 2.45; CI,
1.07e5.62) was positively associated and time to discuss HPV
with patients/parents (OR ¼ .70; CI, .50e.99), concerns about
efficacy (OR ¼ .65; CI, .45e.94), discomfort discussing STIs with
parents (OR ¼ .33; CI, .16e.70) were negatively associated with
vaccine recommendation. Obstetrics/gynecology (OR ¼ .25; CI,
.09e.73), family medicine specialty (OR ¼ .24; CI, .94e.63), and
physicians who saw primarily non-Hispanic black patients (OR¼
.15; CI, .04e.52) were less likely to recommend vaccination in the
final regression model (Table 2). The model explained 34% of the
variance in recommending vaccination.
Catch-up vaccination
Eighty-six percent of physicians reported that they recom-
mend HPV vaccination to adolescent girls aged 13e14. Having
a family medicine clinical specialty was the only demographic
characteristic associated with HPV vaccine recommendation in
the first multivariable model and thus was included in the final
regression model (Table 1). Concerns that teens will practice
riskier sexual behaviors (OR ¼ .57; 95% CI, .37e.87) and
discomfort discussing STIs with parents (OR ¼ .47; 95% CI,
.24e.93) were negatively associated with recommending the
HPV vaccine. Family medicine specialty (OR ¼ .20; CI, .06e.62)
was less likely to recommend vaccination in the final regression
model (Table 2). The overall model explained 29% of the variance
in recommending vaccination.
A vast majority (91%) of physicians reported recommending
HPV vaccination for adolescent girls aged 15e17. Being a family
medicine physician was the only factor associated with recom-
mending HPV vaccination for adolescent girls 15e17 years of age
in the first multivariable model (Table 1). In the final model,
family medicine clinical specialty (OR ¼ .13; CI, .03e.53)
remained significant and, comparedwith pediatricians, were less
likely to recommend the HPV vaccination for adolescent girls
15e17 years of age (Table 2). The model explained 29% of the
variability in HPV vaccine recommendation. For each logistic
regression model, convergence criterion for logistic regression
was satisfied and likelihood ratio test indicated a good model fit.
Discussion
Although provider recommendation of the HPV vaccine does
not necessarily guarantee uptake, some research suggests that
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such recommendations play an important role in whether an
individual initiates and completes the three-dose vaccine series
[27,28]. Thus, identifying barriers to recommendation is vital,
especially among populations at greatest risk for both non-
vaccination and downstream negative health outcomes [29,30].
The focus on HPV vaccine recommendation patterns for low-
income adolescents can help frame strategies to increase
recommendation, and ultimately vaccination, for this vulnerable
population.
Interestingly, no factors were associated with recommenda-
tion of the HPV vaccine across all four age groups. Largely, this
finding is unclear, but may be related to the way in which HPV
vaccine recommendations are categorized (early, target, and
catch-up) and provider’s perceptions of HPV risk and the
appropriateness of recommending vaccination based on those
age-specific categories. Common factors were found however
across some groups. Discomfort discussing STIs with parents was
negatively associated with HPV vaccine recommendation for all
groups, except the late catch-up group. That is, the more
discomfort physicians felt discussing STIs with the parents of
their early, target, and early catch-up adolescent patients, the
less likely they were to report recommendation of HPV vacci-
nation. In contrast, a positive association was found for discus-
sion of STIs with adolescent girls. The more discomfort
physicians felt discussing STIs with their early and target
adolescent patients, the more likely they were to report recom-
mendation of the HPV vaccine. One possible explanation for this
finding is that physicians may be more likely to incorporate the
HPV vaccine into the immunization schedule for younger
adolescents, making discussion of HPV specifically less of
a priority. Previous research suggests that being uncomfortable
discussing the sexual nature of HPV infection may prevent some
physicians from recommending vaccination [16]. The findings of
this study were mixed in that being uncomfortable discussing
STIs with adolescent girls increased recommendation, whereas
discomfort with parents decreased recommendation. Nonethe-
less, these findings may suggest a need for patient-provider
communication interventions around sexual health so that the
patient and parent are fully informed about all aspects of HPV
before vaccination, including the sexual nature of transmission.
Difficulty ensuring completion of the three-dose vaccine
series, which is typically administered over a 6-month period,
was negatively associated with vaccine recommendation only for
early adolescent girls. The more difficult physicians perceived it
was for early adolescents to complete the vaccine series, the less
likely they were to recommend vaccination. According to the
National Immunization Survey-Teen, HPV vaccine initiation
significantly increased from 2010 to 2011, but completion rates
remained stable at about 70% [2,5]. To address this challenge in
the clinical environment, it may be important to have procedures
in place to more readily ensure vaccine completion such as
scheduling follow-up doctor visits to coincide with vaccination
schedules and send parents mail, text, or e-mail reminders
[23,31,32].
Concerns about HPV vaccine efficacy were negatively associ-
ated with HPV recommendation only among target group
adolescent girls. Despite studies documenting 95e100% HPV
vaccine efficacy rates, doubts remain about its usefulness
Table 1
Sociodemographic and clinical predictors of physician reported recommendation of the HPV vaccine for low-income adolescent girls
Characteristic Ages 9e10 unadjusted
ORs (95% CI)
Ages 11e12 unadjusted
ORs (95% CI)
Ages 13e14 unadjusted
ORs (95% CI)
Ages 15e17 unadjusted
ORs (95% CI)
Physician age 1.01 (.99e1.04) .99 (.95e1.02) .96 (.90e1.01) .99 (.92e1.06)
Physician gender
Male (reference) 1.00 1.00 1.00 1.00
Female .91 (.54e1.54) 1.53 (.71e3.27) 2.69 (.65e11.14) 4.90 (.77e31.17)
Physician race
White (reference) 1.00 1.00 1.00 1.00
Other 1.68 (1.02e2.77)* .87 (.43e1.78) 2.55 (.72e8.99) 1.25 (.30e5.18)
Physician ethnicity
Non-Hispanic (reference) 1.00 1.00 1.00 1.00
Hispanic 1.43 (.78e2.62) 3.19 (1.09e9.35)* 1.67 (.30e9.29) 1.12 (.18e7.03)
Vaccines for Children provider
Yes (reference) 1.00 1.00 1.00 1.00
No 1.06 (.51e2.19) 1.44 (.48e4.33) 2.69 (.30e24.23) 1.83 (.12e27.55)
Vaccine coordinator in office
Yes (reference) 1.00 1.00 1.00 1.00
No .78 (.35e1.73) .62 (.20e1.96) .45 (.05e3.97) .90 (.05e13.87)
Clinical specialty
Pediatrics (reference) 1.00 1.00 1.00 1.00
Family medicine 1.00 (.46e2.17) .13 (.05e.36)* .05 (.01e.26)* .06 (.01e.35)*
Obstetrics/gynecology 3.37 (1.15e9.88)* .25 (.08e.79)* .37 (.06e2.14) .46 (.04e4.72)
Daily Medicaid patients seen
<15 (reference) 1.00 1.00 1.00 1.00
15e19 1.04 (.54e2.02) 2.11 (.80e5.53) 1.32 (.24e7.25) 1.44 (.16e13.03)
20e29 1.32 (.66e2.62) 1.21 (.47e3.11) .32 (.06e1.60) .23 (.03e1.58)
30 or more 1.19 (.57e2.46) 3.00 (.97e9.26) .36 (.05e2.58) 3.01 (.20e44.04)
Race of majority of patients seen
Non-Hispanic white (reference) 1.00 1.00 1.00 1.00
Non-Hispanic black .68 (.33e1.42) .13 (.03e.47)* .32 (.04e2.36) .20 (.01e3.01)
Hispanic 1.28 (.59e2.77) .27 (.06e1.15) .58 (.05e6.36) .29 (.01e5.68)
Other .69 (.34e1.41) .21 (.06e.75)* .18 (.03e1.08) .14 (.01e7.03)
CI ¼ confidence interval; HPV ¼ human papillomavirus; OR ¼ odds ratios.
* Significant at p  .05.
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[33e36]. This finding is not particularly surprising given that the
longest efficacy follow-up trial spans 8.5 years [37]. As longer
efficacy outcomes become available, such concerns may be less
prominent barriers to vaccine recommendation. Meanwhile, it
appears that providing physicians information about HPV
vaccine efficacy is an important component of interventions to
increase recommendation for adolescent females in the target
group. Physicians who reported higher levels of time constraints
were also less likely to recommend HPV vaccination to target
group adolescent girls. In this situation, preparatory and
supplemental patient-focused educational materials or training
of mid-level providers to discuss vaccination may alleviate this
barrier without compromising comprehensive care to patients.
Concerns that teens will practice risky sexual behaviors were
negatively associated with recommendation of the HPV vaccine
for early catch-up adolescent girls only. Physicians who reported
higher concerns that teens would practice riskier sexual behav-
iors were less likely to report vaccine recommendation.
Informing providers about studies that indicate vaccinated
adolescents understand the need to practice safer sex irre-
spective of HPV vaccination status may help to alleviate this
concern [38e40].
Physicians who reported that the majority of their patients
were of non-Hispanic black race were less likely to recommend
vaccination compared with those who saw a majority of non-
Hispanic white patients for target adolescents only. This
finding is supported by some patient-focused research demon-
strating that black/African-American patients are less likely to
report a provider recommendation for HPV vaccination [13].
Yitalo et al. found that racial/ethnic minorities and non-Hispanic
whites who receive a provider recommendation are equally
likely to vaccinate [4]. This finding highlights the potential
impact of nondisparate recommendation patterns among low-
income adolescent girls regardless of race/ethnicity.
Last, family medicine physicians compared with pediatricians
were less likely to report recommendation of vaccination for all
groups, except the early vaccination group. This finding aligns
with previous research indicating that pediatricians are more
likely to recommend HPV vaccination compared with other
clinical specialties [23]. In general, pediatricians may have more
favorable attitudes toward vaccination because they routinely
administer childhood vaccination. Because family medicine
physicians may see patients across the spectrum of vaccination
categories, it is important that efforts to increase recommenda-
tion of HPV vaccines extend beyond the pediatrician.
There are limitations to this study that should be considered
when interpreting results. First, all data were self-reported,
which may have introduced recall and reporting bias. Second,
catch-up HPV vaccination is recommended through age 26.
However, we were unable to assess factors related to recom-
mendation of HPV vaccination in ages 18e26 as the study was
restricted to adolescents up to age 17. Third, knowledge as
a barrier to HPV vaccine recommendation was not included in
this analysis. Fourth, the generalizability of findings to other
states should be interpreted with caution given state differences
in Medicaid rules and funding. Last, the study sample included
Table 2
Physicians’ reported barriers to recommendation of the HPV vaccine for low-income adolescent girls
Variable Ages 9e10a adjusted
ORs (95% CI)
Ages 11e12b adjusted
ORs (95% CI)
Ages 13e14c adjusted
ORs (95% CI)
Ages 15e17c adjusted
ORs (95% CI)
Barriers
Concerns about safety .66 (.74e1.20) 1.27 (.90e1.79) 1.47 (.90e2.40) 1.26 (.68e2.32)
Concerns about efficacy 1.24 (.96e1.61) .65 (.45e.94)* .63 (.38e1.04) .78 (.41e1.47)
Concern that teen will practice riskier sexual practices 1.06 (.86e1.32) .82 (.61e1.11) .57 (.37e.87)* .71 (.42e1.21)
Adding another vaccine to the schedule .93 (.73e1.17) 1.22 (.87e1.70) 1.11 (.72e1.70) .87 (.49e1.55)
Lack of information about the vaccine .99 (.79e1.24) 1.18 (.85e1.64) 1.08 (.70e1.68) 1.05 (.60e1.83)
Cost of stocking the vaccine 1.13 (.69e1.44) .87 (.62e1.21) 1.06 (.69e1.63) 1.07 (.63e1.81)
Lack of adequate reimbursement for vaccination .73 (.43e1.24) .80 (.39e1.62) .69 (.24e1.98) .32 (.09e1.08)
Lack of timely reimbursement for vaccination 1.46 (.85e2.50) .96 (.46e2.01) .92 (.33e2.58) 1.38 (.50e3.79)
Time it takes to discuss HPV with patients/parents .89 (.69e1.14) .70 (.50e.99)* .91 (.57e1.46) .71 (.39e1.13)
Discomfort discussing STIs with teens 1.75 (1.03e2.97)* 2.45 (1.07e5.62)* 1.99 (.89e4.46) 1.41 (.62e3.20)
Discomfort discussing STIs with parents .44 (.25e.76)* .33 (.16e.70)* .47 (.24e.93)* .61 (.30e1.26)
Difficulty ensuring completion of three-dose vaccination .73 (.58e.92)* 1.01 (.71e1.45) .66 (.40e1.09) .92 (.49e1.73)
Vaccine is not required for school attendance 1.09 (.89e1.34) 1.33 (.97e1.83) 1.28 (.84e1.94) 1.13 (.67e1.88)
Physician race
White (reference) 1.00 d d d
Other 1.46 (.90e2.39)
Physician ethnicity
Non-Hispanic (reference) d 1.00 d d
Hispanic 1.65 (.63e4.31)
Clinical specialty
Pediatrics (reference) 1.00 1.00 1.00 1.00
Family medicine 1.04 (.49e2.21) .24 (.09e.63)* .20 (.06e.62)* .13 (.03e.53)*
Obstetrics/gynecology 2.09 (.76e5.76) .25 (.09e.73)* .44 (.12e1.62) .20 (.03e1.09)
Race of majority of patients seen
Non-Hispanic white (reference) 1.00
Non-Hispanic black d .15 (.04e.52)* d
Hispanic .52 (.13e2.03)
Other .32 (.10e1.07)
CI ¼ confidence interval; HPV ¼ human papillomavirus; OR, odds ratios; STIs ¼ sexually transmitted infections.
a Adjusted for physician race and clinical specialty.
b Adjusted for physician ethnicity, clinical specialty, and race of majority of patients seen.
c Adjusted for clinical specialty.
* Significant at p  .05.
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only those providers that responded to the survey, which may
have biased the results.
Overall, this study demonstrated that efforts to increase HPV
vaccination may need to be targeted by age groups because there
was no single factor that commonly associated with recom-
mendation across all vaccination groups. A barrier of particular
concern relates to provider discussion about the sexual nature of
HPV with parents. Provider-focused communication interven-
tions can be particularly useful in building physicians’ commu-
nication skills surrounding sensitive topics such as HPV. Equally,
it is important to continue to identify and address HPV vaccine
recommendation and administration barriers that are unique to
family medicine physicians as they also have an integral role to
play in efforts to maximize vaccination. Further, increasing
physicians’ understanding and knowledge about adolescent
perceptions of sexual risk-taking after vaccination is important
across all age groups, but especially for those aged 13e14 years. A
communication approach in which physicians engage in active
dialogue with their adolescent patients around vaccination
myths and misconceptions might provide the most promise. The
barriers to HPV vaccine recommendation identified in this study
explained as much as 34% of the variance in recommendation
with a lower explanatory capacity among early adolescents.
Additional research is needed to identify other potentially
important factors that influence provider recommendation of
the HPV vaccine, particularity for low-income adolescent girls.
Future studies that attempt to elucidate reasons for racial
disparities in provider HPV vaccine recommendation practices
are necessary if the promise of HPV vaccines is to be fully real-
ized. Last, in light of the recent recommendation of the HPV
vaccine for adolescent boys, research that examines barriers to
provider recommendation and ultimately vaccination is war-
ranted because findings of this study may not be generalizable to
providers’ recommendation practices for adolescent boys.
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